SCHEMBL265534

SCHEMBL265534

COc1ccc(C(=O)Nc2ccccc2C(=O)N/N=C/c2ccc(C)cc2)cc1

nearest known ligand 0.79

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 10/20 0.79
RAB9A P51151 9/20 0.79
MAPT P10636 7/20 0.79
HPGD P15428 5/20 0.79
KDM4E B2RXH2 4/20 0.79
ALDH1A1 P00352 3/20 0.79
MEN1 O00255 7/20 0.73
KMT2A Q03164 7/20 0.73
PKM P14618 5/20 0.73
SMN1; SMN2 Q16637 2/20 0.73
ALOX12 P18054 1/20 0.73
NPSR1 Q6W5P4 1/20 0.73
POLB P06746 2/20 0.68
LMNA P02545 1/20 0.60
F10 P00742 1/20 0.55
GAA P10253 1/20 0.54
RXFP1 Q9HBX9 1/20 0.53
CYP1A2 P05177 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL265535 1.00 NPC1 (0.79) NPC1RAB9AMAPTHPGDKDM4E
SCHEMBL266874 0.90 MAPT (0.78) NPC1RAB9AMAPTHPGDKDM4E
SCHEMBL266873 0.90 MAPT (0.78) NPC1RAB9AMAPTHPGDKDM4E
SCHEMBL265290 0.90 KDM4E (0.66) NPC1RAB9AMAPTHPGDKDM4E
SCHEMBL265291 0.90 KDM4E (0.66) NPC1RAB9AMAPTHPGDKDM4E
SCHEMBL265728 0.89 PKM (0.72) NPC1RAB9AMAPTHPGDKDM4E
SCHEMBL268949 0.89 MAPT (0.75) NPC1RAB9AMAPTHPGDKDM4E
SCHEMBL265729 0.89 PKM (0.72) NPC1RAB9AMAPTHPGDKDM4E
SCHEMBL268948 0.89 MAPT (0.75) NPC1RAB9AMAPTHPGDKDM4E
SCHEMBL266103 0.87 MAPT (0.69) NPC1RAB9AMAPTHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 NPC1 102/4885RAB9A 883/4885MAPT 4195/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 NPC1 115/4885RAB9A 1362/4885MAPT 4648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.